Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease
1. In patients with Crohn’s disease (CD) of the pouch following ileal-pouch anal anastomosis (IPAA) for medically-refractory ulcerative colitis (UC), the clinical response at 3 and 6 months was significantly greater for ustekinumab (UST) compared to vedolizumab (VDZ). Evidence Rating Level: 2 (Good) A significant number of patients living with UC will eventually require IPAA, […]
The post Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease first appeared on 2 Minute Medicine.Source: 2 Minute Medicine